Entity Detail — Knowledge Graph Node
This page aggregates everything SciDEX knows about SPM: its mechanistic relationships (Knowledge Graph edges), hypotheses targeting it, analyses mentioning it, and supporting scientific papers. The interactive graph below shows its immediate neighbors. All content is AI-synthesized from peer-reviewed literature.
No AI portrait yet
Knowledge base pages for this entity
| Target | Relation | Type | Str |
|---|---|---|---|
| neuroinflammation resolution | prevents | process | 0.70 |
| Source | Relation | Type | Str |
|---|---|---|---|
| No incoming edges | |||
Hypotheses where this entity is a therapeutic target
Scientific analyses that reference this entity
neuropharmacology | 2026-04-13 | 2 hypotheses Top: 0.551
pharmacology | 2026-04-11 | 0 hypotheses
neurodegeneration | 2026-04-04 | 0 hypotheses
neurodegeneration | 2026-04-01 | 14 hypotheses Top: 0.791
Experimental studies targeting or related to this entity
| Experiment | Type | Disease | Score | Feasibility | Model | Status | Est. Cost |
|---|---|---|---|---|---|---|---|
| s:** - ALOX15 overexpression in healthy astrocytes should be protectiv | falsification | Neuroinflammation | 0.400 | 0.50 | mouse | proposed | $200,000 |
| s:** - Compare brain penetration in FcRn+/+ vs FcRn-/- mice with engin | falsification | Neuroinflammation | 0.400 | 0.50 | mouse | proposed | $200,000 |
| s:** - Compare uptake with/without magnetic particles using tight junc | falsification | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $120,000 |
| AAV Serotype Comparison for LRRK2 Knockdown in PD Gene Therapy | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| AAV Serotype Comparison for LRRK2 Knockdown in PD | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| Blood-Based Biomarker Panel for Early AD Detection | clinical | Alzheimer's Disease | 0.400 | 0.50 | cell_line | proposed | $220,000 |
| Blood-Brain Barrier Aging and Neurodegeneration — From Leakage to Neur | validation | Neurodegeneration | 0.400 | 0.50 | cell_line | proposed | $130,000 |
| Gene Therapy: AAV Serotype Comparison for LRRK2 Knockdown | validation | Parkinson's Disease | 0.400 | 0.50 | mouse | proposed | $280,000 |
| Progranulin Replacement Therapy for FTD — Vector Development and Valid | clinical | ALS | 0.400 | 0.50 | human | proposed | $5,460,000 |
Scientific publications cited in analyses involving this entity
| Title & PMID | Authors | Journal | Year | Citations |
|---|---|---|---|---|
| Allosteric properties of mammalian ALOX15 orthologs. [PMID:41654134] | Yang J, Borchert A, Kuhn H | J Biol Chem | 2026 | 1 |
| Genome-Scale Meta-analysis of Host Responses to Staphylococcus aureus Identifies [PMID:40447280] | Russell CD, Goeldner-Thompson S, Smith E | J Infect Dis | 2025 | 1 |
| SBFI26 induces triple-negative breast cancer cells ferroptosis via lipid peroxid [PMID:38516826] | He G, Zhang Y, Feng Y, Chen T, Liu M, Ze | J Cell Mol Med | 2024 | 1 |
| An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wid [PMID:38753766] | Huang Q, Chan KY, Wu J, Botticello-Romer | Science | 2024 | 1 |
| Targeting the transferrin receptor to transport antisense oligonucleotides acros [PMID:39141703] | Barker SJ, Thayer MB, Kim C, Tatarakis D | Sci Transl Med | 2024 | 1 |
| Blood-brain barrier transport using a high affinity, brain-selective VNAR antibo [PMID:33241587] | Stocki P, Szary J, Rasmussen CLM, Demydc | FASEB J | 2021 | 1 |
| Mitochondrial DNA stress triggers autophagy-dependent ferroptotic death. [PMID:32186434] | Li C, Zhang Y, Liu J, Kang R, Klionsky D | Autophagy | 2021 | 1 |
| 5-lipoxygenase pathway and its downstream cysteinyl leukotrienes as potential th [PMID:32222525] | Chen F, Ghosh A, Lin J, Zhang C, Pan Y, | Brain Behav Immun | 2020 | 1 |
| Transferrin receptor 1 in cancer: a new sight for cancer therapy. [PMID:30034931] | Shen Y, Li X, Dong D, Zhang B, Xue Y, Sh | American journal of cancer res | 2018 | 1 |
| Decoding cell death signals in liver inflammation. [PMID:23567086] | Brenner C, Galluzzi L, Kepp O, Kroemer G | J Hepatol | 2013 | 1 |
| Cadmium exposure is associated with impaired ovarian function: Potential role of [PMID:41548307] | ["Li J", "Wang Y", "Huang Y", "Li N", "Z | Journal of hazardous materials | 2026 | 0 |
| A humanized transferrin receptor 1-transferrin model supports functional iron ho [PMID:41338456] | Yesiltepe M, Metkar S, Yin T, Chakrabort | The Journal of biological chem | 2026 | 0 |
| Early hypoxia-induced secretome remodeling reveals adaptive mechanisms and bioma [PMID:41699623] | Wu Q, Jiang Y, Peng L, Dang Y, You C, Li | Molecular brain | 2026 | 0 |
| MITF programs macrophage iron homeostasis to drive gut-liver inflammatory axis i [PMID:41832955] | Han D, Han L, Kang L, Liu J, Zhang N, Tu | Cell reports | 2026 | 0 |
| Ferrostatin-1 alleviates experimental cerebral malaria by regulating immune cell [PMID:41422632] | Yao S, Zhou X, Liao T, Yao C, Sun M, Gou | International journal for para | 2025 | 0 |
| Intestinal mast cell-derived leukotrienes mediate the anaphylactic response to i [PMID:40773543] | Bachtel ND, Cullen JL, Liu M, Erickson S | Science (New York, N.Y.) | 2025 | 0 |
| Dietary Iron Deficiency in Adult Mice Increases Brain Uptake of High-Affinity, A [PMID:41299828] | Kostrikov S, Johnsen KB, Burkhart A, Hel | Journal of neurochemistry | 2025 | 0 |
| A covalent peptide-based lysosome-targeting protein degradation platform for can [PMID:39910101] | Xiao Y, He Z, Li W, Chen D, Niu X, Yang | Nature communications | 2025 | 0 |
| Dapagliflozin attenuates LPS-induced myocardial injury by reducing ferroptosis. [PMID:38743190] | ["Hu K", "Jiang P", "Hu J", "Song B", "H | Journal of bioenergetics and b | 2024 | 0 |
| Ferroptosis promotes valproate-induced liver steatosis in vitro and in vivo. [PMID:39147356] | ["Yan X", "Ma L", "Chen X", "Ren J", "Zh | Food and chemical toxicology : | 2024 | 0 |
Multi-agent debates referencing this entity
closed · Rounds: 4 · Score: 0.30 · 2026-04-21
closed · Rounds: 4 · Score: 0.30 · 2026-04-21
closed · Rounds: 4 · Score: 0.66 · 2026-04-13
closed · Rounds: 4 · Score: 0.83 · 2026-04-06
Hypotheses and analyses mentioning SPM in their description or question text
Score: 0.000 · unknown disease · 2026-04-28
The BBB limits SPM access to brain tissue. Targeted upregulation of lipid transporters (OATP, FATP) or temporary BBB per
Score: 0.000 · unknown disease · 2026-04-28
Astrocytes could be engineered or pharmacologically enhanced to synthesize and deliver SPMs directly to activated microg
Score: 0.000 · unknown disease · 2026-04-28
Chronic pre-treatment with low-dose SPM receptor agonists could prime microglial resolution machinery before neurodegene
Score: 0.000 · unknown disease · 2026-04-28
SPM synthesis enzymes could be targeted to mitochondria in microglia to create high local concentrations at sites of oxi
Score: 0.000 · unknown disease · 2026-04-28
Neurodegeneration disrupts circadian rhythms of SPM synthesis. Chronotherapeutic delivery of SPM precursors or synthesis
Score: 0.000 · unknown disease · 2026-04-28
Senescent glial cells may produce SPM antagonists or resolution inhibitors that block effective inflammation resolution.